Bifogade filer
Kurs
+1,41%
Likviditet
43,4 MSEK
Kalender
Est. tid* | ||
2025-10-23 | 08:00 | Kvartalsrapport 2025-Q3 |
2025-07-17 | 08:00 | Kvartalsrapport 2025-Q2 |
2025-06-25 | - | Årsstämma |
2025-06-05 | - | X-dag ordinarie utdelning HNSA 0.00 SEK |
2025-04-24 | - | Kvartalsrapport 2025-Q1 |
2025-02-06 | - | Bokslutskommuniké 2024 |
2024-10-17 | - | Kvartalsrapport 2024-Q3 |
2024-07-18 | - | Kvartalsrapport 2024-Q2 |
2024-06-28 | - | X-dag ordinarie utdelning HNSA 0.00 SEK |
2024-06-27 | - | Årsstämma |
2024-04-18 | - | Kvartalsrapport 2024-Q1 |
2024-02-02 | - | Bokslutskommuniké 2023 |
2023-10-26 | - | Kvartalsrapport 2023-Q3 |
2023-07-20 | - | Kvartalsrapport 2023-Q2 |
2023-06-15 | - | X-dag ordinarie utdelning HNSA 0.00 SEK |
2023-06-14 | - | Årsstämma |
2023-04-20 | - | Kvartalsrapport 2023-Q1 |
2023-02-02 | - | Bokslutskommuniké 2022 |
2022-10-20 | - | Kvartalsrapport 2022-Q3 |
2022-07-19 | - | Kvartalsrapport 2022-Q2 |
2022-06-17 | - | X-dag ordinarie utdelning HNSA 0.00 SEK |
2022-06-16 | - | Årsstämma |
2022-04-21 | - | Kvartalsrapport 2022-Q1 |
2022-02-03 | - | Bokslutskommuniké 2021 |
2021-10-21 | - | Kvartalsrapport 2021-Q3 |
2021-07-15 | - | Kvartalsrapport 2021-Q2 |
2021-05-14 | - | X-dag ordinarie utdelning HNSA 0.00 SEK |
2021-05-12 | - | Årsstämma |
2021-04-22 | - | Kvartalsrapport 2021-Q1 |
2021-02-04 | - | Bokslutskommuniké 2020 |
2020-10-22 | - | Kvartalsrapport 2020-Q3 |
2020-07-16 | - | Kvartalsrapport 2020-Q2 |
2020-06-24 | - | X-dag ordinarie utdelning HNSA 0.00 SEK |
2020-06-23 | - | Årsstämma |
2020-04-28 | - | Kvartalsrapport 2020-Q1 |
2020-02-06 | - | Bokslutskommuniké 2019 |
2019-10-31 | - | Kvartalsrapport 2019-Q3 |
2019-07-18 | - | Kvartalsrapport 2019-Q2 |
2019-05-23 | - | X-dag ordinarie utdelning HNSA 0.00 SEK |
2019-05-22 | - | Årsstämma |
2019-04-29 | - | Kvartalsrapport 2019-Q1 |
2019-02-08 | - | Bokslutskommuniké 2018 |
2018-11-01 | - | Kvartalsrapport 2018-Q3 |
2018-07-19 | - | Kvartalsrapport 2018-Q2 |
2018-05-30 | - | X-dag ordinarie utdelning HNSA 0.00 SEK |
2018-05-29 | - | Årsstämma |
2018-04-25 | - | Kvartalsrapport 2018-Q1 |
2018-02-14 | - | Bokslutskommuniké 2017 |
2017-12-22 | - | Extra Bolagsstämma 2017 |
2017-11-14 | - | Kvartalsrapport 2017-Q3 |
2017-07-20 | - | Kvartalsrapport 2017-Q2 |
2017-05-24 | - | X-dag ordinarie utdelning HNSA 0.00 SEK |
2017-05-23 | - | Årsstämma |
2017-04-26 | - | Kvartalsrapport 2017-Q1 |
2017-02-15 | - | Bokslutskommuniké 2016 |
2016-11-21 | - | Extra Bolagsstämma 2016 |
2016-11-09 | - | Kvartalsrapport 2016-Q3 |
2016-07-21 | - | Kvartalsrapport 2016-Q2 |
2016-05-11 | - | Årsstämma |
2016-04-28 | - | X-dag ordinarie utdelning HNSA 0.00 SEK |
2016-04-27 | - | Kvartalsrapport 2016-Q1 |
2016-02-18 | - | Bokslutskommuniké 2015 |
2015-10-28 | - | Kvartalsrapport 2015-Q3 |
2015-08-25 | - | Kvartalsrapport 2015-Q2 |
2015-04-17 | - | X-dag ordinarie utdelning HNSA 0.00 SEK |
2015-04-16 | - | Årsstämma |
2015-04-16 | - | Kvartalsrapport 2015-Q1 |
2015-02-05 | - | Bokslutskommuniké 2014 |
2014-07-25 | - | Kvartalsrapport 2014-Q2 |
2014-06-04 | - | X-dag ordinarie utdelning HNSA 0.00 SEK |
2014-06-03 | - | Årsstämma |
2014-03-05 | - | Extra Bolagsstämma 2014 |
2014-02-05 | - | Bokslutskommuniké 2013 |
2013-07-25 | - | Kvartalsrapport 2013-Q2 |
2013-05-07 | - | X-dag ordinarie utdelning HNSA 0.00 SEK |
2013-05-06 | - | Årsstämma |
2013-02-07 | - | Bokslutskommuniké 2012 |
2012-09-28 | - | Kapitalmarknadsdag 2012 |
2012-07-26 | - | Kvartalsrapport 2012-Q2 |
2012-05-14 | - | Årsstämma |
2012-02-09 | - | Bokslutskommuniké 2011 |
2012-01-09 | - | Extra Bolagsstämma 2011 |
2011-07-28 | - | Kvartalsrapport 2011-Q2 |
2011-05-12 | - | Årsstämma |
2011-05-06 | - | X-dag ordinarie utdelning HNSA 0.00 SEK |
2010-04-30 | - | X-dag ordinarie utdelning HNSA 0.00 SEK |
2010-02-10 | - | Bokslutskommuniké 2009 |
2009-07-30 | - | Kvartalsrapport 2009-Q1 |
2009-05-12 | - | Kvartalsrapport 2009-Q2 |
2009-04-30 | - | X-dag ordinarie utdelning HNSA 0.00 SEK |
2009-04-29 | - | Årsstämma |
Beskrivning
Land | Sverige |
---|---|
Lista | Mid Cap Stockholm |
Sektor | Hälsovård |
Industri | Bioteknik |
The J.P. Morgan Healthcare Conference, the largest investment conference in the life science industry, will take place January 11-14, 2021
Lund, Sweden December 23, 2020. Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced that the Company's management team will present at the 39th Annual J.P. Morgan Healthcare Conference 2021.
The company presentation will take place virtually Thursday January 14, 2021 at 7:30 am (EST)/13:30 (CET).
Management will outline Hansa Biopharma's proprietary enzyme technology platform as well as provide a status update on Idefirix[®] (imlifidase), which recently obtained conditional approval in the European Union for enabling kidney transplantation in highly sensitized kidney transplant patients. Imlifidase is additionally being evaluated for further use in other transplantation indications as well as investigated in autoimmune indications and as a pretreatment in gene therapy for inactivation of neutralizing antibodies.
Access to the presentation will be available under Events & Presentations on the Investors section of the company website at www.hansabiopharma.com.
Management will be available for meetings during the J.P. Morgan Conference week. Anne Marie Fields, RX Communication, NYC, will coordinate the schedule on behalf of Hansa Biopharma. Anne Marie can be reached through afields@rxir.com.
In addition to the J.P. Morgan Conference, Hansa Biopharma has been invited to participate in the following conferences during the first half of 2021:- H.C. Wainwright BioConnect Conference on Monday January 11, 2021, with a presentation available at 6:00 am EST /12:00 CET) on the same day
- SEB Healthcare Seminar on Monday January 18, 2021, with a presentation at 10:10 am CET on the same day
- Vator Swiss-Nordic Healthcare Seminar on Thursday February 11, 2021
- Carnegie Nordic Healthcare Seminar on Tuesday March 9, 2021
- Kempen Life Science Conference, Wednesday May 5, 2021
- RBC Global Healthcare Conference on Tuesday, May 19, 2021
Klaus Sindahl, Head of Investor Relations
Hansa Biopharma
Mobile: +46 (0) 709-298 269
E-mail:
Katja Margell
Head of Corporate Communications
Hansa Biopharma
Mobile: +46 (0) 768-198 326
E-mail: